deuterated enzalutamide
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Feb 10, 2017 (NCT03774056)
Timeline
Indications
Mechanism of action
- Androgen ReceptorINHIBITOR
AR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04986176 | Phase 3 | Aug 15, 2021 | Applied Biology, Inc., Hinova Pharmaceuticals, Inc. |
| NCT03851640 | Phase 3 | Jun 30, 2019 | Haisco Pharmaceutical |
| NCT03850795 | Phase 3 | May 31, 2019 | Hinova Pharmaceuticals, Inc. |
| NCT03778047 | Phase 1 | Feb 1, 2018 | Haisco Pharmaceutical |
| NCT03776968 | Phase 1 | Oct 24, 2017 | Haisco Pharmaceutical |
| NCT03774056 | Phase 1 | Feb 10, 2017 | Haisco Pharmaceutical, Sichuan University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Haisco Pharmaceutical | For profit | 4 | 4 | 2 | 2017 |
| Hinova Pharmaceuticals, Inc. | For profit | 2 | 1 | 1 | 2019 |
| Applied Biology, Inc. | For profit | 1 | 1 | 1 | 2021 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1